Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

  Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form   20-F  Business Wire  HYDERABAD, India -- June 27, 2014  Dr. Reddy’s Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2014 was filed with the United States Securities and Exchange Commission on June 26, 2014.  The Annual Report on Form 20-F is also available on Dr. Reddy’s website, www.drreddys.com, and can be accessed by selecting ‘SEC filings’ under the ‘Investors’ Section. ADS holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Company’s registered office or by sending an e-mail to shares@drreddys.com.  Disclaimer  This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.  About Dr. Reddy’s  Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com.  Contact:  Dr. Reddy’s Laboratories Limited Investors and Financial Analysts: Kedar Upadhye, +91-40-66834297 kedaru@drreddys.com or Saunak Savla, +91-40-49002135 saunaks@drreddys.com or Milan Kalawadia (USA), +1 609-375-9831 mkalawadia@drreddys.com or Media: SVS Chowdary, +91-40-49002448 chowdaryl@drreddys.com  
Press spacebar to pause and continue. Press esc to stop.